Federal Register Notice: FDA’s Cardiovascular and Renal Drugs Advisory Committee will meet 6/24, from 8 a.m. to 5 p.m. at the Hilton Washington DC/Silver Spring, Maryland Ballroom, 8727 Colesville Rd., Silver Spring, MD. The committee will discuss safety considerations in the development of ultrasound contrast agents, based on experience with: (1) Lantheus Medical Imaging’s NDA for perflutren lipid microsphere injectable suspension; (2) GE Healthcare’s NDA for perflutren protein-type A microspheres injectable suspension; and (3) Bracco Diagnostics’ IND for sulfur hexafluoride microbubble injection. Contact Elaine Ferguson, (301) 827-7001. To view this notice, click here.